## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($131.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns**
- Source: Simply Wall Street | 20251215T090934 | Somewhat-Bullish | Relevance: 100%
- Neurocrine Biosciences (NBIX) has delivered double-digit shareholder returns over the past year, prompting a re-evaluation of its valuation. The stock appears undervalued based on future growth and earnings potential, with a narrative fair value near $244.8 against a current price of $152.8. However, a different perspective on earnings multiples suggests the stock is already priced at a premium, trading above industry and peer averages, indicating investors are paying for execution risk.

**2. Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology**
- Source: PR Newswire | 20251216T210934 | Bullish | Relevance: 100%
- Neurocrine Biosciences announced a new R&D strategy focused on delivering innovative medicines in neuroscience and endocrinology, aiming for an approved medicine every two years by the end of the decade. The company highlighted its late-stage neuropsychiatry pipeline, including osavampator and direclidine, with Phase 3 data expected in 2027, and expanded its CRF platform for metabolic diseases like obesity. Neurocrine emphasizes its commitment to addressing unmet needs with a diversified portfolio of first- and best-in-class therapies.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | HC Wainwright & | $198 | $168 | +18% |
| 2025-12-12 | Mizuho | $175 | $146 | +20% |
| 2025-12-11 | Stifel | $188 | $183 | +3% |
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | HC Wainwright & | main | Buy |
| 2025-12-12 | Mizuho | main | Neutral |
| 2025-12-11 | Stifel | main | Buy |
| 2025-12-08 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($1.77M) |
| Sells | 4 ($3.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-4.8% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.2M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 5 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 15.5x attractive for 32% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (5 raises, avg +13%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.1B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 5.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 15.5 |
| Current P/E | 20.5 |
| YoY Growth | 32.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.2% to -4.5% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >3.0% for momentum thesis). Underperforming sector by 6.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). MACD histogram bearish (-1.00), momentum weakening. OFD pattern: -F0H (Breakdown).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.53% (CS: 9) | Weak |
| RSI_14 | 37.7 | Neutral |
| MACD Histogram | -1.00 | Bearish |
| vs SMA20 | 0.948x | Below |
| vs SMA50 | 0.973x | Below |
| vs SMA200 | 1.095x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $141.70
- **Stop Loss:** $131.86 (6.9% risk)
- **Target:** $151.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 109
- **Position Value:** $15,445.30
- **Portfolio %:** 15.45%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*